共查询到20条相似文献,搜索用时 46 毫秒
1.
2.
3.
4.
5.
6.
7.
宫颈癌及其癌前病变组织中HPV16 E6、HPV16 E7蛋白的表达及其意义 总被引:4,自引:0,他引:4
目的 探讨宫颈癌及其癌前病变组织中HPV16E6、E7蛋白的表达及其意义。方法 采用免疫组化SP法对15例正常宫颈、25例宫颈上皮内瘤变(C1N)以及61例浸润性宫颈癌组织进行了HPVl6E6、HPVl6E7蛋白表达的检测。结果在正常宫颈、CINI~Ⅱ、CINⅢ及浸润性宫颈癌中,HPVl6E6蛋白的阳性表达率分别为0(0/15)、7.14%(1/14)、36.36%(4/11)、59.02%(36/61);CINⅢ和浸润性宫颈癌中HPVl6E6蛋白阳性表达率明显高于正常宫颈组织和CINI~Ⅱ(P〈0.05);在高、中、低分化宫颈癌中,HPVl6E6蛋白阳性表达率分别为45.45%(5/11)、77.78%(14/18)、53.13%(17/32);HPVl6E6蛋白在不同分化程度的宫颈癌组织中的阳性表达率有显著性差异(P〈0.05),但HPVl6E6蛋白表达与官颈癌组织分化程度无明显相关性(ys=0.123),HPVl6E6蛋白阳性表达率与宫颈癌临床分期和淋巴结转移无关(P〉0.05)。HPVl6E7蛋白在正常宫颈上皮、CINI-Ⅱ、CIN Ⅲ及浸润性富颈癌组织中的阳性表达率分别为20.00%(3/15)、42.86%(6/14)、63.64%(7/11)、57.38%(35/61),HPVl6E7蛋白在不同宫颈组织中的阳性表达率无明显差异(P=0.05);HPVl6E7蛋白的表达与富颈癌临床分期、淋巴结转移和组织分化均无关(P〉0.05)。结论 HPVl6E6蛋白的检测有可能作为宫颈癌前病变转归的指标。 相似文献
8.
Marina N. Nikiforova MD Marcos Lepe MD Lindsey A. Tolino BS MBA Megan E. Miller BS N. Paul Ohori MD Abigail I. Wald PhD Michael S. Landau MD Cihan Kaya PhD Umberto Malapelle PhD Claudio Bellevicine MD PhD Giancarlo Troncone MD Yuri E. Nikiforov MD PhD Zubair Baloch MD PhD 《Cancer cytopathology》2021,129(1):33-42
9.
10.
11.
12.
13.
14.
目的:调查苏州地区女性人乳头瘤病毒(HPV)感染现状和亚型分布情况,为宫颈癌防治政策提供理论依据。方法:2016年7月至2019年3月对苏州地区20~65岁的女性进行随机抽样调查。采用PCR体外扩增和DNA反向点杂交相结合的HPV基因分型检测技术,分析苏州地区HPV的感染状况。结果:在符合条件的4 275名女性中共检出964例HPV阳性者,阳性率为22.55%(964/4275)。其中高危型HPV(HR-HPV)阳性有812例,占HPV感染人群84.23%(812/964)。在检出的23种HPV亚型中,按感染率由高到低排列分别为52、81、16、58、53、51、68、56、42、33、18、66、59、11、43、31、39、6、45、35、82、83、73亚型。不同年龄段HPV感染率不同,以20~29岁年龄段感染率最高(21.26%)(135/635),其次为40~49岁年龄段(20.27%)(238/1 174),HPV感染中以单一感染为主642例(66.60%)(642/964)。结论:HPV感染在苏州地区呈现单一、高危亚型感染为主的特征,该地区HPV感染亚型主要为52、81、16、58、53、51。 相似文献
15.
HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status 下载免费PDF全文
Lyndsay Ann Richardson MSc Mariam El‐Zein PhD Agnihotram V. Ramanakumar PhD Samuel Ratnam PhD Ghislain Sangwa‐Lugoma MD Adhemar Longatto‐Filho PhD Marly Augusto Cardoso PhD Francois Coutlée MD PhD Eduardo L. Franco DrPH The PEACHS Study Consortium 《Cancer cytopathology》2015,123(12):745-754
16.
Szarewski A Poppe WA Skinner SR Wheeler CM Paavonen J Naud P Salmeron J Chow SN Apter D Kitchener H Castellsagué X Teixeira JC Hedrick J Jaisamrarn U Limson G Garland S Romanowski B Aoki FY Schwarz TF Bosch FX Harper DM Hardt K Zahaf T Descamps D Struyf F Lehtinen M Dubin G;HPV PATRICIA Study Group 《International journal of cancer. Journal international du cancer》2012,131(1):106-116
In the Phase III PATRICIA study (NCT00122681), the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) was highly efficacious against HPV‐16/18 infections and precancerous lesions in women HPV‐16/18 deoxyribose nucleic acid (DNA) negative and seronegative at baseline. We present further data on vaccine efficacy (VE) against HPV‐16/18 in the total vaccinated cohort including women who may have been exposed to HPV‐16/18 infection before vaccination. In women with no evidence of current or previous HPV‐16/18 infection (DNA negative and seronegative), VE was 90.3% (96.1% confidence interval: 87.3–92.6) against 6‐month persistent infection (PI), 91.9% (84.6–96.2) against cervical intraepithelial neoplasia (CIN)1+ and 94.6% (86.3–98.4) against CIN2+ [97.7% (91.1–99.8) when using the HPV type assignment algorithm (TAA)]. In women HPV‐16/18 DNA negative but with serological evidence of previous HPV‐16/18 infection (seropositive), VE was 72.3% (53.0–84.5) against 6‐month PI, 67.2% (10.9–89.9) against CIN1+, and 68.8% (?28.3–95.0) against CIN2+ [88.5% (10.8–99.8) when using TAA]. In women with no evidence of current HPV‐16/18 infection (DNA negative), regardless of their baseline HPV‐16/18 serological status, VE was 88.7% (85.7–91.1) against 6‐month PI, 89.1% (81.6–94.0) against CIN1+ and 92.4% (84.0–97.0) against CIN2+ [97.0% (90.6–99.5) when using TAA]. In women who were DNA positive for one vaccine type, the vaccine was efficacious against the other vaccine type. The vaccine did not impact the outcome of HPV‐16/18 infections present at the time of vaccination. Vaccination was generally well tolerated regardless of the woman's HPV‐16/18 DNA or serological status at entry. 相似文献
17.
喉癌及其转移淋巴结中检出HPV DNA 总被引:1,自引:0,他引:1
应用PCR技术对喉原发癌、转移癌、癌旁正常粘膜和声带息肉石蜡包埋组织中的HPVDNA进了检测,结果:40例喉癌标本中24例检出HPVDNA,阳性率60%(24/40),其中HPV6/11、16/18DNA阳性者分别为6例(5%)和18例(45%);12例喉癌颈转移淋巴结6例检出HPVDNA,这6例均为HPV16/18;10例癌旁正常粘膜和10例声带息肉均阴性。说明喉癌的发生及其淋巴结转移可能与HPV16/18感染有关。 相似文献
18.
19.